Radioligand therapy significantly prolongs progression-free survival in metastatic GEP-NETs. Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared with targeted therapy with everolimus.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Results of the Phase III COMPETE clinical trial show that the targeted radiotherapeutic agent [177Lu]Lu-edotreotide significantly prolonged progression-free survival in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) compared with targeted therapy with everolimus.
- Ponto de atenção: radioligand.
- Ponto de atenção: therapy.
- Ponto de atenção: significantly.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/f6af3fc0-483e-4190-98f8-f6fc36168b7c.png)
